{"id":"cldm-1-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Peeling"},{"rate":null,"effect":"Oiliness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin works by binding to the bacterial 50S ribosomal subunit and inhibiting peptide bond formation, thereby preventing bacterial protein synthesis. This bacteriostatic action is effective against a broad range of gram-positive and anaerobic bacteria. The 1% gel formulation is designed for topical application to treat acne and other skin infections.","oneSentence":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:20.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Bacterial skin infections"}]},"trialDetails":[{"nctId":"NCT02557399","phase":"PHASE4","title":"DUAC® Early Onset Efficacy Study in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-07","conditions":"Acne Vulgaris","enrollment":350},{"nctId":"NCT01445301","phase":"PHASE3","title":"Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-27","conditions":"Acne Vulgaris","enrollment":800},{"nctId":"NCT01400932","phase":"PHASE3","title":"Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07","conditions":"Acne Vulgaris","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CLDM 1% gel","genericName":"CLDM 1% gel","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris, Bacterial skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}